Atalanta banks $97M to send RNAi drugs into the brain

RNAi Biotech Atalanta Unveils $97M to Reach the Clinic in Two Rare Neuro Diseases

The structure of Atalanta Therapeutics’ RNA interference drugs enables them to distribute broadly and deeply into brain tissue. Lead programs for Huntington’s disease and a rare inherited form epilepsy are on track to enter the clinic this year. The post RNAi Biotech Atalanta Unveils $97M to Reach the Clinic in Two Rare Neuro Diseases appeared first on MedCity News.

Boston biotech Atalanta raises $97M to bring CNS drugs into clinic

The Boston biotech is the latest to capitalize on the growing interest behind RNA interference (RNAi)-based medicines.

Atalanta banks $97M to send RNAi drugs into the brain

The startup says its specially constructed RNAi therapies can get deep into brain tissue, yielding new ways to treat neurological conditions like Huntington’s.

Atalanta Therapeutics raises $97 million to advance RNAi therapies for CNS disorders

The oversubscribed Series B will boost the clinical development of two RNAi therapies for epilepsy and Huntington’s disease

Atalanta Therapeutics Unveils $97M to Reach the Clinic in Two Rare Neuro Diseases

Using RNA to interfere with a gene’s expression of disease-causing proteins is a validated therapeutic approach, but so far, the products in this drug class only address liver proteins. Reducing levels of certain proteins in the central nervous system (CNS) could offer a new way to treat neurological disorders. The challenge facing drug developers is […] The post Atalanta Therapeutics Unveils $97M to Reach the Clinic in Two Rare Neuro Diseases a…

Atalanta secures $97m in Series B round to advance RNAi therapies

Sanofi Ventures and EQT Life Sciences jointly led the funding round. New investors like Novartis Venture Fund, RiverVest Venture Partners, Mirae Asset Financial Group, abrdn-managed funds, GHR Foundation, The post Atalanta Therapeutics secures $97m in Series B round to advance RNAi therapies appeared first on Pharmaceutical Business review.